Open access
3,692
Views
25
CrossRef citations to date
0
Altmetric
Review
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
Christopher P WildingDivision of Molecular Pathology, The Institute of Cancer Research, London, UKView further author information
, Mark L ElmsDivision of Molecular Pathology, The Institute of Cancer Research, London, UKView further author information
, Ian JudsonDepartment of Medical Oncology, Sarcoma Unit, The Royal Marsden Hospital, London, UKView further author information
, Aik-Choon TanDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USAView further author information
, Robin L JonesDepartment of Medical Oncology, Sarcoma Unit, The Royal Marsden Hospital, London, UKView further author information
& Paul H HuangDivision of Molecular Pathology, The Institute of Cancer Research, London, UKCorrespondence[email protected]
View further author information
View further author information
Pages 971-991
|
Received 30 Jul 2019, Accepted 28 Oct 2019, Published online: 13 Nov 2019
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.